Phaseline

Companies › Sun Pharma Japan

Sun Pharma Japan: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Deuruxolitinib
JAK1 inhibitor
JAK1Phase 3Alopecia AreataFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07617597DeuruxolitinibPhase 3Alopecia AreataImmunologyFeb 2028

Targets

JAK1 (1)

Companies with the same targets

Incyte Pfizer AbbVie Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Dizal Pharmaceuticals Alfasigma Takeda Chengdu Zenitar Biomedical Technology Eli Lilly

Companies built like this

Priovant Therapeutics Alfasigma Biopharma Plasma Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.